These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3860153)

  • 21. In vivo follow up of the cytotoxic effect of ricin toxin vectorized by multivalent hybrid antibody on target cells.
    Moa G; Nicolae M; Laky M; Bancu A; Moraru I
    Immunol Lett; 1988 Feb; 17(2):177-82. PubMed ID: 3258846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates.
    Thiesen HJ; Juhl H; Arndt R
    Cancer Res; 1987 Jan; 47(2):419-23. PubMed ID: 3539323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of murine EL4 leukemia in ascitic form with anti-Thy 1.2 specific immunotoxins.
    Marches R; Mota G; Margineanu M; Stavri H; Savi G; Nicolae M; Bancu A; Moraru I
    Neoplasma; 1990; 37(5):573-8. PubMed ID: 2234217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperthermia potentiates the activity of immunotoxin conjugates against common acute lymphoblastic leukaemia cells in vitro.
    Herrmann RP; Pelham JM; Raphael CL; Meyer BF; Davis RE
    Ann N Y Acad Sci; 1987; 511():428-35. PubMed ID: 2964219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using anti-idiotypic antibodies coupled to the A chain of ricin.
    DeShambo RM; Krolick KA
    J Immunol; 1986 Nov; 137(10):3135-9. PubMed ID: 3490511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.
    Ciavarra RP; Vitetta ES; Forman J
    J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy.
    Elliott TJ; Glennie MJ; McBride HM; Stevenson GT
    J Immunol; 1987 Feb; 138(3):981-8. PubMed ID: 2433338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preferential expression of IgG1 antibodies specific for L2C leukaemia IgM idiotypic determinants in tumour-protected strain 2 guinea-pigs.
    Ricardo MJ; Grimm DT
    Immunology; 1983 Apr; 48(4):763-9. PubMed ID: 6187671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen.
    Youle RJ; Uckun FM; Vallera DA; Colombatti M
    J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
    Ramakrishnan S; Bjorn MJ; Houston LL
    Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies as carriers of toxins.
    Uhr JW; Fulton RJ; Till MA; May RD; Vitetta ES
    Prog Clin Biol Res; 1989; 288():403-12. PubMed ID: 2785694
    [No Abstract]   [Full Text] [Related]  

  • 36. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.
    Stong RC; Youle RJ; Vallera DA
    Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.
    Stevenson GT; Elliott EV; Stevenson FK
    Fed Proc; 1977 Aug; 36(9):2268-71. PubMed ID: 69552
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective killing of leukaemia cells by antibody-toxin conjugates: implications for autologous bone marrow transplantation.
    Krolick KA; Uhr JW; Vitetta ES
    Nature; 1982 Feb; 295(5850):604-5. PubMed ID: 7035973
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters.
    Sanfilippo F; Kao KJ; Pizzo SV; Collins JJ
    J Natl Cancer Inst; 1980 Mar; 64(3):547-53. PubMed ID: 6928240
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.